REFERENCES
1. Salmon D, Mondelli MU, Maticic M, Arends JE. ESCMID Study Group for Viral Hepatitis. The benefits of hepatitis C virus cure: every rose has thorns. J Viral Hepat 2018;25:320-8.
2. Dang H, Yeo YH, Yasuda S, et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west. Hepatology 2020;71:1910-22.
3. Park H, Wang W, Henry L, Nelson DR. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic hepatitis c in the united states. Hepatology 2019;69:1032-45.
4. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
5. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
6. Finkelmeier F, Dultz G, Peiffer KH, et al. Risk of de novo hepatocellular carcinoma after hcv treatment with direct-acting antivirals. Liver Cancer 2018;7:190-204.
7. Rutledge SM, Zheng H, Li DK, Chung RT. No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. Hepatoma Res 2019;5:31.
8. Semmler G, Binter T, Kozbial K, et al. Noninvasive risk stratification after HCV eradication in patients with advanced chronic liver Disease. Hepatology 2021;73:1275-89.
9. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
10. Rinaldi L, Di Francia R, Coppola N, et al. Hepatocellular carcinoma in hcv cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and posssible meanings. WCRJ 2016; 3:748.
11. Kassas M, Tawheed A, Eltabbakh M, Kaseb A. Hepatitis C antiviral therapy in patients with successfully treated hepatocellular carcinoma: dancing with wolves. J Hepatocell Carcinoma 2019;6:183-91.
12. Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut 2022;71:593-604.
13. Hernaez R, Thimme R. End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma. Gut 2022;71:454-6.
14. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
15. Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856-8.
16. Ravi S, Axley P, Jones D, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152:911-2.
17. Cardoso H, Vale AM, Rodrigues S, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016;65:1070-1.
18. Cabibbo G, Petta S, Barbàra M, et al. ITA. LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int 2017;37:1157-66.
19. Calleja JL, Crespo J, Rincón D, et al. Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort. J Hepatol 2017;66:1138-48.
20. Lashen SA, Shamseya MM, Madkour MA. Hepatocellular carcinoma occurrence/recurrence after direct-acting antivirals for hepatitis C in egyptian cohort: single-center experience. Dig Dis 2019;37:488-97.
21. Hassany SM, Hassan W, Abo-Alam H, et al. Direct-acting antiviral drugs and occurrence of hepatocellular carcinoma: unjust or oppressed. Infect Drug Resist 2020;13:1873-80.
22. Nakano M, Koga H, Ide T, et al. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study. Cancer Med 2019;8:2646-53.
23. Chan PPY, Levy MT, Shackel N, Davison SA, Prakoso E. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Hepatobiliary Pancreat Dis Int 2020;19:541-6.
24. Ahn YH, Lee H, Kim DY, et al. Independent risk factors for hepatocellular carcinoma recurrence after direct-acting antiviral therapy in patients with chronic hepatitis C. Gut Liver 2021;15:410-9.
25. Kamal A, Elmoety AAA, Rostom YA, Shater MS, Lashen SA. Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study. Clin Exp Hepatol 2021;7:66-73.
26. Degasperi E, D'Ambrosio R, Iavarone M, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol 2019;17:1183-1191.e7.
27. Mariño Z, Darnell A, Lens S, et al. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. J Hepatol 2019;70:874-84.
28. Sangiovanni A, Alimenti E, Gattai R, et al. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. J Hepatol 2020;73:593-602.
29. Tani J, Senoh T, Moriya A, et al. Long-term outcomes and evaluation of hepatocellular carcinoma recurrence after hepatitis C virus eradication by direct-acting antiviral treatment: all kagawa liver disease group (AKLDG) study. Cancers (Basel) 2021;13:2257.
30. Ogawa E, Nakamuta M, Furusyo N, et al. Kyushu University Liver Disease Study (KULDS) Group. Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals. J Gastroenterol Hepatol 2022;37:190-9.
31. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 2016;65:859-60.
32. El Kassas M, Funk AL, Salaheldin M, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative analysis. J Viral Hepat 2018;25:623-30.
33. Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021;13:1743-52.
34. Bielen R, Moreno C, Van Vlierberghe H, et al. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: a belgian experience. J Viral Hepat 2017;24:976-81.
35. Fatima T, Mumtaz H, Khan MH, et al. Patterns of hepatocellular carcinoma after direct antiviral agents and pegylated-interferon therapy. Cureus 2020;12:e11565.
36. Nahon P, Layese R, Bourcier V, et al. ANRS CO12 CirVir Group. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in Patients with cirrhosis included in surveillance programs. Gastroenterology 2018;155:1436-1450.e6.
37. Kwong AJ, Kim WR, Flemming JA. De novo hepatocellular carcinoma among liver transplant registrants in the direct acting antiviral era. Hepatology 2018;68:1288-97.
38. Lim N, Singh D, Jackson S, Lake JR. Recurrence of hepatocellular carcinoma in hepatitis C virus (HCV) liver transplant recipients treated with pretransplant direct-acting antiviral (DAA) therapy. Gastrointest Tumors 2020;7:134-43.
39. Kuo YH, Wang JH, Chang KC, et al. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Invest New Drugs 2020;38:202-10.
40. Teng W, Jeng WJ, Yang HI, et al. Interferon is superior to direct acting antiviral therapy in tertiary prevention of early recurrence of hepatocellular carcinoma. Cancers (Basel) 2019;12:23.
41. Karbeyaz F, Kissling S, Jaklin PJ, et al. Rates of hepatocellular carcinoma after start of treatment for chronic hepatitis C remain high with direct acting antivirals: analysis from a swiss liver transplant center. J Hepatocell Carcinoma 2021;8:565-74.
42. Ji D, Chen GF, Niu XX, et al. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021;10:100090.
43. Lithy RM, Elbaz T, H Abdelmaksoud A, et al. Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals. Eur J Gastroenterol Hepatol 2022;34:227-34.
44. Rinaldi L, Perrella A, Guarino M, et al. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. J Transl Med 2019;17:292.
45. Tayyab GUN, Rasool S, Nasir B, Rubi G, Abou-Samra AB, Butt AA. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens. BMC Gastroenterol 2020;20:93.
46. Cheung MCM, Walker AJ, Hudson BE, et al. HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.
47. collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts); Electronic address: [email protected]. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-40.
48. Mettke F, Schlevogt B, Deterding K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther 2018;47:516-25.
49. Carrat F, Fontaine H, Dorival C, et al. French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019;393:1453-64.
50. Miuma S, Miyamoto J, Taura N, et al. Influence of interferon-free direct-acting antiviral therapy on primary hepatocellular carcinoma recurrence: a landmark time analysis and time-dependent extended cox proportional hazards model analysis. Intern Med 2020;59:901-7.
51. Kuromatsu R, Ide T, Okamura S, et al. Hepatitis C virus elimination using direct acting antivirals after the radical cure of hepatocellular carcinoma suppresses the recurrence of the cancer. Cancers (Basel) 2022;14:2295.
52. Cabibbo G, Celsa C, Calvaruso V, et al. Rete SICILIA SELEZIONE TERAPia - HCV (RESIST-HCV) and Italian Liver Cancer (ITA. LI.CA.) Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 2019;71:265-73.
53. Lin WC, Lin YS, Chang CW, et al. Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. PLoS One 2020;15:e0233212.
54. Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter north american cohort study. Gastroenterology 2019;156:1683-1692.e1.
55. Nault JC, Nahon P. Can we move on from the discussion of direct antiviral agents and risk of hepatocellular carcinoma recurrence? Gastroenterology 2019;156:1558-60.
56. Serviddio G, Villani R. The effect of direct-acting antivirals on hepatocellular carcinoma recurrence: still waiting for the turning point. Hepatobiliary Surg Nutr 2019;8:525-6.
57. Mun EJ, Green P, Berry K, Ioannou GN. No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. Eur J Gastroenterol Hepatol 2019;31:47-52.
58. Piñero F, Boin I, Chagas A, et al. Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher wait-list progression or posttransplant recurrence. Liver Transpl 2020;26:640-50.
59. Ikeda K, Kawamura Y, Kobayashi M, et al. direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2017;62:2932-42.
60. Lui FH, Moosvi Z, Patel A, et al. Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis. Ann Gastroenterol 2020;33:293-8.
61. Ochi H, Hiraoka A, Hirooka M, et al. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol 2021;56:90-100.
62. Ikenaga H, Uchida-Kobayashi S, Tamori A, et al. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat 2022;29:52-9.
63. Chen YS, Huang KH, Wang PM, et al. The impact of direct-acting antiviral therapy on the risk of recurrence after curative resection in patients with hepatitis-C-virus-related early stage hepatocellular carcinoma. Medicina (Kaunas) 2022;58:259.
64. Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol 2018;69:345-52.
65. Calvaruso V, Cabibbo G, Cacciola I, et al. Rete Sicilia Selezione Terapia-HCV (RESIST-HCV). Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155:411-421.e4.
66. Huang P, Liu M, Zang F, et al. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: a comprehensive analysis. Carcinogenesis 2018;39:1497-505.
67. Jain A, Miller D, Schreibman I, et al. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy? Hepatol Int 2019;13:190-8.
68. Toyoda H, Hiraoka A, Uojima H, et al. Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response. Hepatol Commun 2021;5:1290-9.
69. Mecci AJ, Kemos P, Leen C, et al. HCV Research UK. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Aliment Pharmacol Ther 2019;50:204-14.
70. Toyoda H, Kumada T, Tada T, et al. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: a prospective observational study. Liver Int 2019;39:448-54.
71. Minami T, Tateishi R, Nakagomi R, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol 2016;65:1272-3.
72. Nagata H, Nakagawa M, Asahina Y, et al. Ochanomizu Liver Conference Study Group. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017;67:933-9.
73. Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
74. Cammà C, Leandro G. Direct antiviral agents and risk of HCC: waiting for Godot. J Hepatol 2018;68:614-6.
75. Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology 2018;67:2244-53.
76. Nishibatake Kinoshita M, Minami T, Tateishi R, et al. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy. J Hepatol 2019;70:78-86.
77. Gorgen A, Galvin Z, Huang AC, et al. The impact of direct-acting antivirals on overall mortality and tumoral recurrence in patients with hepatocellular carcinoma listed for liver transplantation: an international multicenter study. Transplantation 2020;104:2087-96.
78. Janjua NZ, Wong S, Darvishian M, et al. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. J Viral Hepat 2020;27:781-93.
79. Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment. Mol Clin Oncol 2020;12:111-6.
80. Tahata Y, Sakamori R, Urabe A, et al. Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. Hepatol Res 2020;50:1118-27.
81. Wu KC, Lee IC, Chi CT, et al. Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. Am J Cancer Res 2021;11:5526-42.
82. Chi CT, Chen CY, Su CW, et al. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. J Microbiol Immunol Infect 2021;54:385-95.
83. Ismail MS, Mohamed I, Polychronopoulou E, et al. Outcomes in the era of interferon-free direct-acting antiviral therapy after liver transplantation in patients with hepatitis C virus and hepatocellular carcinoma. J Hepatocell Carcinoma 2021;8:701-11.
84. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol ;2017:25-32.
85. Mashiba T, Joko K, Kurosaki M, et al. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? PLoS One 2018;13:e0194704.
86. Innes H, Barclay ST, Hayes PC, et al. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. J Hepatol 2018;68:646-54.
87. Nagaoki Y, Imamura M, Nishida Y, et al. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: comparison with interferon-based therapy. J Med Virol 2019;91:650-8.
88. Singer AW, Reddy KR, Telep LE, et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 2018;47:1278-87.
89. Frazzoni L, Sikandar U, Metelli F, et al. Hepatocellular carcinoma recurrence after hepatitis c virus therapy with direct-acting antivirals. a systematic review and meta-analysis. J Clin Med 2021;10:1694.
90. Sapena V, Rios J, Torres F, et al. Reply to: “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules - a response”. J Hepatol 2019;71:447-8.
91. Shiha G, Mousa N, Soliman R, Nnh Mikhail N, Adel Elbasiony M, Khattab M. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study. J Viral Hepat 2020;27:671-9.
92. Tani J, Morishita A, Sakamoto T, et al. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncol Lett 2020;19:2205-12.
93. Hamoir C, Horsmans Y, Stärkel P, Dahlqvist G, Negrin Dastis S, Lanthier N. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents. Acta Gastroenterol Belg 2021;84:25-32.
95. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007;22 Suppl 1:S108-11.
96. Zhao P, Malik S, Xing S. Epigenetic mechanisms involved in HCV-induced hepatocellular carcinoma (HCC). Front Oncol 2021;11:677926.
97. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
98. Hoshida Y, Villanueva A, Sangiovanni A, et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013;144:1024-30.
99. Nakagawa S, Wei L, Song WM, et al. Precision Liver Cancer Prevention Consortium. Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition. Cancer Cell 2016;30:879-90.
100. Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular mechanisms of hepatocarcinogenesis following sustained virological response in patients with chronic hepatitis C virus infection. Viruses 2018;10:531.
101. Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J. Hepatitis C virus and hepatocellular carcinoma: when the host loses its grip. Int J Mol Sci 2020;21:3057.
102. Hengst J, Strunz B, Deterding K, et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur J Immunol 2016;46:2204-10.
103. Reig M, Boix L, Mariño Z, Torres F, Forns X, Bruix J. Liver cancer emergence associated with antiviral treatment: An immune surveillance failure? Semin Liver Dis 2017;37:109-18.
104. Owusu Sekyere S, Schlevogt B, Mettke F, et al. HCC Immune surveillance and antiviral therapy of hepatitis C virus infection. Liver Cancer 2019;8:41-65.
105. Wedemeyer H, Khera T, Strunz B, Björkström NK. Reversal of immunity after clearance of chronic HCV infection-all reset? Front Immunol 2020;11:571166.
106. Perez S, Kaspi A, Domovitz T, et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet 2019;15:e1008181.
107. Hamdane N, Jühling F, Crouchet E, et al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology 2019;156:2313-2329.e7.
108. Li MM, Tang YQ, Gong YF, et al. Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma. BMC Cancer 2019;19:851.
109. Okamoto Y, Shinjo K, Shimizu Y, et al. Hepatitis virus infection affects DNA methylation in mice with humanized livers. Gastroenterology 2014;146:562-72.
110. Zheng Y, Hlady RA, Joyce BT, et al. DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. Clin Epigenetics 2019;11:145.
111. Ponziani FR, Putignani L, Paroni Sterbini F, et al. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther 2018;48:1301-11.
112. Tovo PA, Garazzino S, Daprà V, et al. Chronic HCV infection is associated with overexpression of human endogenous retroviruses that persists after drug-induced viral clearance. Int J Mol Sci 2020;21:3980.
113. Santangelo L, Bordoni V, Montaldo C, et al. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. Liver Int 2018;38:1741-50.
114. Butt AS, Sharif F, Abid S. Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: biologically plausible or an epiphenomenon? World J Hepatol 2018;10:267-76.
115. Takeda H, Takai A, Iguchi E, et al. Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus. Carcinogenesis 2021;42:672-84.
116. Sung PS, Shin EC. Immunological mechanisms for hepatocellular carcinoma risk after direct-acting antiviral treatment of hepatitis C virus infection. J Clin Med 2021;10:221.
117. Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment. J Hepatocell Carcinoma 2020;7:45-76.
118. Aydin Y, Chatterjee A, Chandra PK, et al. Interferon-alpha-induced hepatitis C virus clearance restores p53 tumor suppressor more than direct-acting antivirals. Hepatol Commun 2017;1:256-69.
119. Aydin Y, Chedid M, Chava S, et al. Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture. Sci Rep 2017;7:9223.
120. Aydin Y, Kurt R, Song K, et al. Hepatic stress response in HCV infection promotes STAT3-mediated inhibition of HNF4A-miR-122 feedback loop in liver fibrosis and cancer progression. Cancers (Basel) 2019;11:1407.
121. Pinyol R, Torrecilla S, Wang H, et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2021;75:865-78.
122. Villani R, Facciorusso A, Bellanti F, et al. DAAs rapidly reduce inflammation but increase serum vegf level: a rationale for tumor risk during anti-HCV treatment. PLoS One 2016;11:e0167934.
123. Faillaci F, Marzi L, Critelli R, et al. Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals. Hepatology 2018;68:1010-24.
124. Elmasry S, Wadhwa S, Bang BR, et al. Detection of occult hepatitis c virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation. Gastroenterology 2017;152:550-553.e8.
125. Yousif MM, Elsadek Fakhr A, Morad EA, et al. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents. Infez Med 2018;26:237-43.
126. Abd Alla MDA, Dawood RM, Rashed HAE, et al. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes. Arch Virol 2021;166:1071-81.
127. Matsuura K, Sawai H, Ikeo K, et al. Japanese genome-wide association study group for viral hepatitis. genome-wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection. Gastroenterology 2017;152:1383-94.
128. Villani R, Vendemiale G, Serviddio G. Molecular mechanisms involved in HCC recurrence after direct-acting antiviral therapy. Int J Mol Sci 2018;20:49.
129. Rinaldi L, Nevola R, Franci G, et al. Risk of hepatocellular carcinoma after HCV clearance by direct-acting antivirals treatment predictive factors and role of epigenetics. Cancers (Basel) 2020;12:1351.
130. Oe N, Takeda H, Eso Y, Takai A, Marusawa H. Clinical and molecular basis of hepatocellular carcinoma after hepatitis C virus eradication. Pathogens 2022;11:430.
131. Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F. Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows. World J Gastroenterol 2018;24:2582-95.
132. Audureau E, Carrat F, Layese R, et al. ANRS CO12 CirVir group. Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. J Hepatol 2020;73:1434-45.
133. D’Ambrosio R, Degasperi E, Lampertico P. Predicting hepatocellular carcinoma risk in patients with chronic HCV infection and a sustained virological response to direct-acting antivirals. J Hepatocell Carcinoma 2021;8:713-39.
134. Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49.
135. Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol 2019;25:4199-212.
136. Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol 2022;76:353-63.
137. Huo TI, Liao JI, Ho SY. Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? J Hepatol 2022;76:987-8.
138. Khakoo SI. Immunotherapy for hepatocellular carcinoma: a “CRAFITY” approach to patient stratification. Hepatobiliary Surg Nutr 2022;11:327-9.
139. Thorsson V, Gibbs DL, Brown SD, et al. Cancer genome atlas research network. The immune landscape of cancer. Immunity 2018;48:812-830.e14.
140. Bidkhori G, Benfeitas R, Klevstig M, et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc Natl Acad Sci U S A 2018;115:E11874-83.
141. Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol 2020;72:215-29.
142. Jiang Y, Sun A, Zhao Y, et al. Chinese Human Proteome Project (CNHPP) Consortium. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 2019;567:257-61.
143. Sun R, Xu Y, Zhang H, et al. Mechanistic modeling of gene regulation and metabolism identifies potential targets for hepatocellular carcinoma. Front Genet 2020;11:595242.
144. Krishnan MS, Rajan Kd A, Park J, et al. Genomic analysis of vascular invasion in HCC reveals molecular drivers and predictive biomarkers. Hepatology 2021;73:2342-60.
145. Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy. Gastroenterology 2019;156:492-509.
146. Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: a step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93.
147. Heinrich S, Craig AJ, Ma L, Heinrich B, Greten TF, Wang XW. Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. J Hepatol 2021;74:700-15.
148. Dong X, Wang F, Liu C, et al. Single-cell analysis reveals the intra-tumor heterogeneity and identifies MLXIPL as a biomarker in the cellular trajectory of hepatocellular carcinoma. Cell Death Discov 2021;7:14.
149. Alvarez M, Benhammou JN, Darci-Maher N, et al. Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival. Genome Med 2022;14:50.
150. Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. Int J Clin Oncol 2022;27:1101-9.
151. Galle PR, Abou-Alfa GK. Decision making in systemic therapy of hepatocellular carcinoma: Should we pay attention to disease aetiology? J Hepatol 2021;75:763-4.
152. Kolly P, Waidmann O, Vermehren J, et al. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a European multicentre study. J Hepatol 2017;67:876-8.
153. Adhoute X, Penaranda G, Raoul JL, et al. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol 2018;30:368-75.
154. Tsai PC, Huang CF, Yu ML. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy. J Hepatol 2017;66:464.
155. Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology 2019;156:2149-57.
156. Ogawa E, Furusyo N, Nomura H, et al. Kyushu University Liver Disease Study (KULDS) Group. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther 2018;47:104-13.
157. Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA initiation after curative treatment and its relationship with the recurrence of HCV-related HCC. J Hepatocell Carcinoma 2020;7:347-60.
158. Wörns MA, Galle PR, Zeuzem S, Schirmacher P, Manns M, Vogel A. Drug treatment for chronic hepatitis C infection and cancer risk. Dtsch Arztebl Int 2017;114:597-602.
159. Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, Singal AG. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther 2018;48:127-37.
160. Turgeon MK, Shah SA, Delman AM, et al. Optimal timing of administration of direct-acting antivirals for patients with hepatitis c-associated hepatocellular carcinoma undergoing liver transplantation. Ann Surg 2021;274:613-20.
161. Kogiso T, Sagawa T, Kodama K, et al. Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virus. JGH Open 2019;3:52-60.
162. Kuo MJ, Mo LR, Chen CL. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. BMC Cancer 2021;21:250.
163. Sanduzzi-Zamparelli M, Mariño Z, Lens S, et al. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. J Hepatol 2022;76:874-82.
164. Ramadori G, Bosio P, Moriconi F, Malik IA. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy. BMC Cancer 2018;18:257.
165. Samonakis DN, Koulentaki M, Coucoutsi C, et al. Clinical outcomes of compensated and decompensated cirrhosis: a long term study. World J Hepatol 2014;6:504-12.
166. Innes H, McDonald S, Hayes P, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol 2017;66:19-27.
167. Zayedi E, Makvandi M, Teimoori A, et al. Prevalence of hepatitis C virus among HIV-infected patients. Iran J Microbiol 2020;12:156-63.
168. Minami T, Tateishi R, Fujiwara N, et al. Impact of obesity and heavy alcohol consumption on hepatocellular carcinoma development after HCV eradication with antivirals. Liver Cancer 2021;10:309-19.
169. Semmler G, Meyer EL, Kozbial K, et al. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2022;76:812-21.
170. Kouroumalis E, Voumvouraki A. Hepatitis C virus: a critical approach to who really needs treatment. World J Hepatol 2022;14:1-44.
171. van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017;66:485-93.
172. Degasperi E, Galmozzi E, Pelusi S, et al. Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated With DAAs. Hepatology 2020;72:1912-23.
173. D’Ambrosio R, Degasperi E, Anolli MP, et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2022;76:302-10.
174. Abdel-Razik A, Shabana W, El Nakib AM, et al. De novo hepatocellular carcinoma in hepatitis C-related cirrhosis: are advanced glycation end products a key driver? Front Cell Infect Microbiol 2021;11:662431.
175. Váncsa S, Németh D, Hegyi P, et al. Diabetes mellitus increases the risk of hepatocellular carcinoma after direct-acting antiviral therapy: systematic review and meta-analysis. Front Med (Lausanne) 2021;8:744512.
176. Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DT. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022;28:96-107.
177. Salmon-Ceron D, Nahon P, Layese R, et al. ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups. Human immunodeficiency virus/hepatitis C virus (HCV) Co-infected patients with cirrhosis are no longer at higher risk for hepatocellular carcinoma or end-stage liver disease as compared to HCV mono-infected patients. Hepatology 2019;70:939-54.
178. Corma-Gómez A, Macías J, Lacalle-Remigio JR, et al. RIS-HEP13 and GEHEP 011 study groups. Human immunodeficiency virus (HIV) infection is associated with lower risk of hepatocellular carcinoma after sustained virological response to direct-acting antivirals in hepatitis c infected patients with advanced fibrosis. Clin Infect Dis 2021;73:e2109-16.
179. Quaranta MG, Ferrigno L, Monti M, et al. PITER Collaborating Group. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. Hepatol Int 2020;14:362-72.
180. Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology 2019;157:1264-1278.e4.
181. Flisiak R, Zarębska-Michaluk D, Janczewska E, et al. Five-year follow-up of cured HCV patients under real-world interferon-free therapy. Cancers (Basel) 2021;13:3694.
182. Pons M, Rodríguez-Tajes S, Esteban JI, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol 2020;72:472-80.
183. Piñero F, Mendizabal M, Ridruejo E, et al. LALREAN. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver Int 2019;39:1033-43.
184. Singh S, Nautiyal A, Loke YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. Frontline Gastroenterol 2018;9:262-70.
185. Burlone ME, Fangazio S, Croce A, et al. Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment. Hepatoma Res 2020;6:3.
186. Pazgan-simon M. Direct acting antivirals therapy and hepatocellular carcinoma risk in patients with hepatitis C virus. Hepatoma Res 2020;6:17.
188. Yoo SH, Kwon JH. The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C. Hepatoma Res 2020;6:9.
189. D'Ambrosio R, Ioannou GN. Hepatocellular carcinoma risk, outcomes, and screening after hepatitis C eradication. Hepatol Commun 2021;5:1465-8.
190. Sánchez-Azofra M, Fernández I, García-Buey ML, et al. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. Liver Int 2021;41:2885-91.
191. Alonso López S, Manzano ML, Gea F, et al. A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis. Hepatology 2020;72:1924-34.
192. Ioannou GN, Tang W, Beste LA, et al. Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis. JAMA Netw Open 2020;3:e2015626.
193. Muzica CM, Stanciu C, Huiban L, et al. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: a debate near the end. World J Gastroenterol 2020;26:6770-81.
194. Rinaldi B, Rosato V, Galiero R, Vetrano E, Fasano M, Rinaldi L. Editorial - direct-acting antivirals therapy in HCV patients with HCC: lights and shadow. Eur Rev Med Pharmacol Sci 2021;25:7622-5.
195. John BV. No association between direct-acting antivirals and hepatocellular carcinoma progression on the waiting list: time to put this controversy to rest? Liver Transpl 2020;26:621-3.
196. Celsa C, Stornello C, Giuffrida P, et al. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence. Ann Hepatol 2022;27 Suppl 1:100568.
197. Dajti E, Ravaioli F, Festi D, Colecchia A. Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk. Hepatobiliary Surg Nutr 2020;9:505-7.
198. Compagnoni S, Bruno EM, Madonia G, Cannizzaro M, Madonia S. Direct antiviral agents in hepatitis C virus related liver disease: don’t count the chickens before they're hatched. World J Gastroenterol 2021;27:2771-83.
199. Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M. Hepatocellular carcinoma recurrence in HCV patients treated with direct antiviral agents. Viruses 2019;11:406.
200. Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: the debate continues - a mini-review. J Adv Res 2019;17:43-8.
201. Kamal A, Elsheaita A, Abdelnabi M. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate. World J Clin Cases 2022;10:1764-74.
202. Lee CH, Kim IH. Direct-acting antiviral therapy and risk of hepatocellular carcinoma recurrence in patients with chronic hepatitis C. Gut Liver 2021;15:327-8.
203. Meier V, Bürger E, Mihm S, Saile B, Ramadori G. Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection. J Med Virol 2003;69:50-8.
204. You MW, Kim KW, Shim JJ, Pyo J. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: a systematic review and time-to-event meta-analysis. J Gastroenterol Hepatol 2021;36:601-8.
205. Janjua NZ, Chong M, Kuo M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol 2017;66:504-13.
206. Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43.
207. Poynard T, Munteanu M, Ratziu V, et al. Truth survival in clinical research: an evidence-based requiem? Ann Intern Med 2002;136:888-95.
